| Pharmaceutical Information |
| Drug Name |
Ceftobiprole |
| Drug ID |
BADD_D00404 |
| Description |
Ceftobiprole is a cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus. It was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development. Ceftobiprole is the first cephalosporin to demonstrate clinical efficacy in patients with infections due to methicillin-resistant staphylococci and, if approved by regulatory authorities, is expected to be a useful addition to the armamentarium of agents for the treatment of complicated skin infections and pneumonia. |
| Indications and Usage |
For the treatment of serious bacterial infections in hospitalised patients. |
| Marketing Status |
Not Available |
| ATC Code |
Not Available |
| DrugBank ID |
DB04918
|
| KEGG ID |
D08885
|
| MeSH ID |
C443755
|
| PubChem ID |
135413542
|
| TTD Drug ID |
D0CI9T
|
| NDC Product Code |
Not Available |
| Synonyms |
ceftobiprole | BAL9141 | BAL 9141 |
|
| Chemical Information |
| Molecular Formula |
C20H22N8O6S2 |
| CAS Registry Number |
209467-52-7 |
| SMILES |
C1CNCC1N2CCC(=CC3=C(N4C(C(C4=O)NC(=O)C(=NO)C5=NSC(=N5)N)SC3)C(=O)O)C2=O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
